Form 8-K - Current report:
SEC Accession No. 0001193125-26-127609
Filing Date
2026-03-27
Accepted
2026-03-27 08:03:02
Documents
13
Period of Report
2026-03-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vor-20260326.htm   iXBRL 8-K 57896
2 EX-10.1 vor-ex10_1.htm EX-10.1 338765
3 EX-10.2 vor-ex10_2.htm EX-10.2 224658
4 EX-99.1 vor-ex99_1.htm EX-99.1 19490
5 GRAPHIC img246614764_0.gif GRAPHIC 22046
  Complete submission text file 0001193125-26-127609.txt   874394

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vor-20260326.xsd EX-101.SCH 24847
16 EXTRACTED XBRL INSTANCE DOCUMENT vor-20260326_htm.xml XML 4705
Mailing Address 500 BOYLSTON STREET SUITE 1350 BOSTON MA 02116
Business Address 500 BOYLSTON STREET SUITE 1350 BOSTON MA 02116 617-655-6580
Vor Biopharma Inc. (Filer) CIK: 0001817229 (see all company filings)

EIN.: 811591163 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39979 | Film No.: 26801143
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)